Literature DB >> 24410482

Harnessing proteasome dynamics and allostery in drug design.

Maria Gaczynska1, Pawel A Osmulski.   

Abstract

SIGNIFICANCE: The proteasome is the essential protease that is responsible for regulated cleavage of the bulk of intracellular proteins. Its central role in cellular physiology has been exploited in therapies against aggressive cancers where proteasome-specific competitive inhibitors that block proteasome active centers are very effectively used. However, drugs regulating this essential protease are likely to have broader clinical usefulness. The non-catalytic sites of the proteasome emerge as an attractive alternative target in search of highly specific and diverse proteasome regulators. RECENT ADVANCES: Crystallographic models of the proteasome leave the false impression of fixed structures with minimal molecular dynamics lacking long-distance allosteric signaling. However, accumulating biochemical and structural observations strongly support the notion that the proteasome is regulated by precise allosteric interactions arising from protein dynamics, encouraging the active search for allosteric regulators. Here, we discuss properties of several promising compounds that affect substrate gating and processing in antechambers, and interactions of the catalytic core with regulatory proteins. CRITICAL ISSUES: Given the structural complexity of proteasome assemblies, it is a painstaking process to better understand their allosteric regulation and molecular dynamics. Here, we discuss the challenges and achievements in this field. We place special emphasis on the role of atomic force microscopy imaging in probing the allostery and dynamics of the proteasome, and in dissecting the mechanisms involving small-molecule allosteric regulators. FUTURE DIRECTIONS: New small-molecule allosteric regulators may become a next generation of drugs targeting the proteasome, which is critical to the development of new therapies in cancers and other diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24410482      PMCID: PMC4241894          DOI: 10.1089/ars.2013.5816

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  135 in total

1.  Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

Authors:  K B Kim; J Myung; N Sin; C M Crews
Journal:  Bioorg Med Chem Lett       Date:  1999-12-06       Impact factor: 2.823

2.  Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

Authors:  J Myung; K B Kim; K Lindsten; N P Dantuma; C M Crews
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 3.  Imaging and manipulation of biological structures with the AFM.

Authors:  Dimitrios Fotiadis; Simon Scheuring; Shirley A Müller; Andreas Engel; Daniel J Müller
Journal:  Micron       Date:  2002       Impact factor: 2.251

Review 4.  Proteasome plasticity.

Authors:  Michael H Glickman; Dina Raveh
Journal:  FEBS Lett       Date:  2005-06-13       Impact factor: 4.124

5.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

Authors:  A K Nussbaum; T P Dick; W Keilholz; M Schirle; S Stevanović; K Dietz; W Heinemeyer; M Groll; D H Wolf; R Huber; H G Rammensee; H Schild
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 6.  Proteasomal AAA-ATPases: structure and function.

Authors:  Shoshana Bar-Nun; Michael H Glickman
Journal:  Biochim Biophys Acta       Date:  2011-07-23

7.  Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Authors:  N E Franke; D Niewerth; Y G Assaraf; J van Meerloo; K Vojtekova; C H van Zantwijk; S Zweegman; E T Chan; C J Kirk; D P Geerke; A D Schimmer; G J L Kaspers; G Jansen; J Cloos
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

8.  Structural studies of HIV-1 Tat protein.

Authors:  P Bayer; M Kraft; A Ejchart; M Westendorp; R Frank; P Rösch
Journal:  J Mol Biol       Date:  1995-04-07       Impact factor: 5.469

9.  Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

Authors:  M Orlowski; C Cardozo; C Michaud
Journal:  Biochemistry       Date:  1993-02-16       Impact factor: 3.162

10.  Purification and characterization of a protein inhibitor of the 20S proteasome (macropain).

Authors:  M Chu-Ping; C A Slaughter; G N DeMartino
Journal:  Biochim Biophys Acta       Date:  1992-03-12
View more
  10 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 2.  Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.

Authors:  Oliver Drews; Heinrich Taegtmeyer
Journal:  Antioxid Redox Signal       Date:  2014-10-01       Impact factor: 8.401

3.  Computational Study on the Dynamics of Mycobacterium Tuberculosis RNA Polymerase Assembly.

Authors:  Sneha Bheemireddy; Narayanaswamy Srinivasan
Journal:  Methods Mol Biol       Date:  2022

4.  PSMB2 knockdown suppressed proteasome activity and cell proliferation, promoted apoptosis, and blocked NRF1 activation in gastric cancer cells.

Authors:  Zimeng Liu; Changda Yu; Zhibing Chen; Chuanwen Zhao; Lin Ye; Chen Li
Journal:  Cytotechnology       Date:  2022-06-27       Impact factor: 2.040

Review 5.  Allostery Modulates Interactions between Proteasome Core Particles and Regulatory Particles.

Authors:  Philip Coffino; Yifan Cheng
Journal:  Biomolecules       Date:  2022-05-30

6.  Substituted quinolines as noncovalent proteasome inhibitors.

Authors:  Tanner J McDaniel; Theresa A Lansdell; Amila A Dissanayake; Lauren M Azevedo; Jacob Claes; Aaron L Odom; Jetze J Tepe
Journal:  Bioorg Med Chem       Date:  2016-04-02       Impact factor: 3.641

Review 7.  Structural Insights into Substrate Recognition and Processing by the 20S Proteasome.

Authors:  Indrajit Sahu; Michael H Glickman
Journal:  Biomolecules       Date:  2021-01-24

8.  Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein.

Authors:  Przemysław Karpowicz; Paweł A Osmulski; Julia Witkowska; Emilia Sikorska; Małgorzata Giżyńska; Agnieszka Belczyk-Ciesielska; Maria E Gaczynska; Elżbieta Jankowska
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

9.  Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding.

Authors:  Antonio Di Dato; Alessandra Cunsolo; Marco Persico; Anna Maria Santoro; Alessandro D'Urso; Danilo Milardi; Roberto Purrello; Manuela Stefanelli; Roberto Paolesse; Grazia R Tundo; Diego Sbardella; Caterina Fattorusso; Massimo Coletta
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

10.  New Peptide-Based Pharmacophore Activates 20S Proteasome.

Authors:  Paweł A Osmulski; Przemysław Karpowicz; Elżbieta Jankowska; Jonathan Bohmann; Andrew M Pickering; Maria Gaczyńska
Journal:  Molecules       Date:  2020-03-22       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.